|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Abgenix Immunex Corporation |
| Information provided by: | Abgenix |
| ClinicalTrials.gov Identifier: | NCT00061126 |
Purpose
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
| Condition | Intervention | Phase |
|
Prostate Cancer |
Drug: ABX-EGF |
Phase II |
| MedlinePlus related topics: | Cancer Prostate Cancer |
| Drug Information available for: | Panitumumab |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Alabama | |||||
| University of Alabama at Birmingham | |||||
| Birmingham, Alabama, United States, 35294 | |||||
| United States, California | |||||
| Stanford Medical Center | |||||
| Stanford, California, United States, 94303 | |||||
| UCLA School of Medicine | |||||
| Los Angeles, California, United States, 90095 | |||||
| United States, Florida | |||||
| Advanced Research Institute | |||||
| New Port Richey, Florida, United States, 34652 | |||||
| United States, Pennsylvania | |||||
| University of Pittsburgh Cancer Institute, Hillman Cancer Center | |||||
| Pittsburgh, Pennsylvania, United States, 15232 | |||||
| Fox Chase Cancer Center | |||||
| Philadelphia, Pennsylvania, United States, 19111 | |||||
| United States, Texas | |||||
| Urology San Antonio Research | |||||
| San Antonio, Texas, United States, 78229 | |||||
| United States, Washington | |||||
| Madigan Army Medical Center | |||||
| Tacoma, Washington, United States, 98431 | |||||
| University of Washington | |||||
| Seattle, Washington, United States, 98109 | |||||
| Abgenix |
| Immunex Corporation |
More Information
| Study ID Numbers: | ABX-0310, ABX-EGF |
| First Received: | May 21, 2003 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00061126 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|